XXB750

DRUG3 trials

Sponsors

Novartis Pharma AG, Novartis Pharmaceuticals

Conditions

Heart FailureHeart Failure With Reduced Ejection Fraction (HFrEF)XXB750 in Healthy Participantsor Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)

Phase 1

Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF)

CompletedNCT05328752

Novartis PharmaceuticalsHeart Failure With Reduced Ejection Fraction (HFrEF), or Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)

Start: 2022-05-17End: 2024-01-18Updated: 2025-09-30

Safety, Tolerability, and Pharmacokinetics of XXB750 in Healthy Participants

CompletedNCT06558097

Novartis PharmaceuticalsXXB750 in Healthy Participants

Start: 2020-07-29End: 2023-03-31Updated: 2024-08-16

Phase 2

A multi-center, randomized, placebo- and active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure

CompletedCTIS2023-504678-39-00

Novartis Pharma AGHeart Failure

Start: 2024-03-13End: 2024-11-08Target: 424Updated: 2024-11-08